Table 4 Comparison of outcomes of BL/BLI administration between propensity score-matched ABPC/SBT and PIPC/TAZ cohorts.
From: Ampicillin sulbactam impacts serum potassium level comparable to piperacillin tazobactam
Propensity score-matched | |||
|---|---|---|---|
ABPC/SBT cohort (n = 59) | PIPC/TAZ cohort (n = 59) | Result of analysis | |
Change in SPL (mEq/L) | − 0.28 ± 0.47 | − 0.35 ± 0.51 | P = 0.443 |
Percent decrease in SPL (%) | 10.7 ± 7.0 | 11.0 ± 9.7 | P = 0.822 |
Incidence of hypokalemia during BL/BLI administration (%) | 25.4 | 27.1 | P = 1.000, OR = 1.091, 95%CI = 0.443–2.696 |
Incidence of hypokalemia within 3 days after starting administration (%) | 3.4 | 8.5 | P = 0.439, OR = 0.382, 95%CI = 0.035–2.453 |
Incidence of hypokalemia within 5 days after starting administration (%) | 18.6 | 16.9 | P = 1.000 OR = 1.122, 95%CI = 0.392–3.249 |
Incidence of hypokalemia within 7 days after starting administration (%) | 20.3 | 18.6 | P = 1.000, OR = 1.113, 95%CI = 0.405–3.090 |
Incidence of hypokalemia within 14 days after starting administration (%) | 23.7 | 23.7 | P = 1.000, OR = 1.000, 95%CI = 0.392–2.554 |
